Home
Storia in 1 fonti
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
Raccontata da
cnbc.com
Timeline cronologica
- ·
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
- ·
Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs
Novo Nordisk CEO Mike Doustdar told Jim Cramer about developments in obesity treatment.